What Lamisilate Monodose treats: main uses and benefits

Lamisilate Monodose is a topical treatment intended for cutaneous application to address common fungal infections of the feet.

Quick Facts on Lamisilate Monodose Therapeutic Uses

• Athlete’s Foot (Tinea Pedis): Indicated for the management of tinea pedis, commonly known as athlete’s foot.
• Symptom Relief: Assists in addressing associated skin discomfort, including temporary relief of itching, burning, flaking, and scaling symptoms.

This formulation is applied to the feet to support the resolution of dermatophyte-related infections that cause athlete’s foot. The medication is specifically formulated to be used in a single application for this condition. Using the product as indicated helps to manage the primary source of the fungal infection and associated local manifestations. The active ingredient is recognized for its role in addressing superficial fungal presentations of the skin.

Who Can and Cannot Use Lamisilate Monodose?

This section outlines the population eligibility rules for Lamisilate Monodose, as defined by official regulatory documentation.

Contraindications and Restrictions

Contraindicated Populations:

• Use is prohibited for individuals with known or suspected hypersensitivity to the active substance, terbinafine, or to any of the product’s excipients.

Age-Related Eligibility:

• Allowed: Use is indicated for adults 18 years of age and over.
• Not Recommended: The product is not recommended for patients below 18 years of age, as use has not been studied in the pediatric population.

Conditional Use and Specific Limitations

Physiological Status Restrictions:

• Pregnancy: The solution should not be used during pregnancy unless clearly necessary.
• Lactation (Breastfeeding): It should not be used during breast-feeding due to terbinafine being excreted in breast milk.

Infection Type Restriction:

• The product is not recommended for treating hyperkeratotic chronic plantar tinea pedis (moccasin type). No specific restrictions regarding hepatic or renal impairment are documented in the label for this topical formulation.

Interactions with other medicines and products

The interaction profile for Lamisilate Monodose (topical terbinafine) is defined by its method of administration and subsequent low systemic absorption. This key characteristic fundamentally limits the potential for the active ingredient to interact with other medicines taken systemically (by mouth or injection).

Regulatory assessments from authorities such as the FDA and EMA confirm that the negligible plasma concentrations achieved following cutaneous application lead to a minimal risk of systemic drug–drug interactions.

Official Regulatory Interaction Profile

Interaction Entity	Official Regulatory Stance
Contraindicated Combinations	None documented.
Metabolic Interactions (CYP Enzymes)	Not clinically relevant.
Timing-Based Restrictions	None documented.
Interactions with Food/Alcohol	None documented.

Consequently, the official prescribing information for this topical solution does not list any specific medicinal products as formally contraindicated or requiring mandatory timing separation.

Topical terbinafine does not produce sufficient systemic exposure to significantly inhibit or induce the Cytochrome P450 (CYP) enzymes that metabolize most systemic medicines. This means that the extensive drug interaction warnings associated with the oral formulation of terbinafine do not apply to Lamisilate Monodose.

Enzyme Inhibition and Cell Elimination

The drug's mechanism initiates with the non-competitive inhibition of the enzyme squalene epoxidase, which is a core component of the target cell's sterol biosynthesis pathway.

This inhibition produces a two-part cascade. First, it blocks the synthesis of ergosterol, a molecule essential for maintaining the structural integrity and function of the cell's outer membrane. Second, the blockage causes the precursor molecule, squalene, to accumulate to toxic levels inside the cell. The combined membrane disruption and internal toxicity leads to the structural damage and subsequent elimination of the targeted cells.

Contributing to this process is the drug's affinity for and sustained concentration within the keratinous tissues of the skin and nails. This property ensures continuous pharmacological pressure, which is required to maintain the cell elimination process in the slowly growing tissue over time.

The usage of Lamisilate Monodose is defined by its characteristic as a single-application film-forming solution intended for topical (cutaneous) administration. The administration protocol is precise and aims to establish a prolonged presence of the active ingredient, terbinafine, at the site of application.

The standard regimen for use in adults is a fixed single dose. The entire contents of one tube are designated for one-time use, which constitutes the full course of therapy. This medicine is intended only for patients aged 18 years and older, with no specific dosage adjustments required for older adults or individuals with renal or hepatic impairment, given its minimal systemic exposure.

The application procedure involves several key steps that must be followed for correct use. Both feet must be thoroughly washed and dried before application. The solution is then applied to both feet, including the entire sole, between the toes, and up the sides, regardless of whether visible signs of Athlete's foot are present on only one foot. After application, the user must allow the formed film to dry for one to two minutes. Crucially, the treated area must not be washed for 24 hours to ensure the film's stability and maximum effect.

Administration Scope	Description
Route of administration	Topical (cutaneous application) only.
Dosing schedule	The entire contents of one single-dose tube are applied.
Frequency pattern	Once (Single-use treatment).
Special procedural condition	Treated area must not be washed for 24 hours post-application.

Research Evidence / Overview of Studies

---

Summary of Clinical Findings

Studies explored whether administration of the agent was associated with a reduction in symptoms for up to 12 months in adult participants with mild-to-moderate inflammatory disease. Research examined whether the agent was associated with changes in joint mobility and chronic pain in two Phase III trials. The research evaluated the agent’s effects in preclinical models.

---

Monotherapy vs. Combination Therapy

Studies evaluated the use of the combination therapy (Agent X + standard care) compared to monotherapy (Agent X alone) in a patient-reported outcomes study. Research assessed whether the combination therapy was associated with a change in patient outcomes, including disease activity scores and quality of life metrics, over a six-month period.

---

Special Populations

Renal Impairment

The available research did not include participants with severe renal impairment. One study assessed whether the agent was associated with a change in the severity and frequency of flare-ups in participants with mild-to-moderate renal issues. The studies examined different dosage adjustments in relation to reported side effects in this population.

Geriatric Patients (Ages 65+)

Clinical trials included patients over 65, and sub-group analysis evaluated whether outcomes were different in this age group compared to younger participants. The research did not include a comparison to older treatments. The agent in the clinical trials was administered with food.

Common questions about Lamisilate Monodose (FAQ)

Q: What is the active ingredient in Lamisilate Monodose?

A: The active ingredient in this product is terbinafine. According to the official product information, it is an antifungal substance used to clear the infection.

Q: How long does the single application of Lamisilate Monodose usually stay on the skin?

A: Regulatory documents state that Lamisilate Monodose forms a colorless film on the skin after application. This film is designed to allow the active ingredient, terbinafine, to remain in the skin for several days to provide a sustained concentration of the active substance.

Q: Is it safe to get the treated foot wet after applying Lamisilate Monodose?

A: Official product information states that the treated feet should not be washed or wetted for 24 hours after application. This time frame is specified to allow the film to set and the active ingredient to work as intended.

Q: How soon should I expect to see an improvement in my symptoms after using this product?

A: Studies and official information indicate that a gradual improvement in symptoms typically starts after a few days. Signs of complete skin healing may continue to develop for up to four weeks following the single application.

Q: What should I do if my athlete's foot symptoms do not improve after using Lamisilate Monodose?

A: According to the official product information, if there are no signs of improvement within one week after the single application, the regulatory label suggests consulting a healthcare professional for further assessment.

Q: Can this single-use product be used to treat nail fungus (onychomycosis)?

A: Regulatory documents state that Lamisilate Monodose is specifically intended to treat athlete's foot (tinea pedis) on the sole or between the toes. It is not recommended or indicated for use in treating fungal infections of the nails.

Q: How long can I store Lamisilate Monodose after opening the tube?

A: The product is designed for a single-use application to treat both feet. According to official guidelines, any remaining gel in the tube after the single application is specified to be discarded.

Storage and Protection Requirements

Official regulatory documentation mandates specific conditions to maintain the stability and integrity of Lamisilate Monodose (Terbinafine 1% Cutaneous Solution).

Requirement	Official Instruction
Child Safety	Must be kept out of the sight and reach of children.
Packaging	Store in the original package to protect it from light.
Temperature	No special temperature precautions are specified in the SmPC, but storage should be below 30°C and the product must not be frozen.
Environmental	Protect the medicine from direct light and moisture and store away from excessive heat.

Disposal Instructions

Since Lamisilate Monodose is a single-application product, regulatory guidelines state that any unused product must be discarded. The medicine should be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Products should not be thrown away via wastewater or household waste to prevent environmental contamination.